Comparison of olanzapine 2.5 mg and 5 mg in the prevention of chemotherapy-induced nausea and vomiting: a Japanese nationwide database study
Open Access
- 18 August 2024
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 29 (11) , 1762-1773
Abstract
Background: Olanzapine is prescribed as prophylaxis for chemotherapy-induced nausea and vomiting at a dose of 2.5 or 5 mg in Asian countries. We compared the effectiveness of olanzapine 2.5 mg and 5 mg in preventing chemotherapy-induced nausea and vomiting among patients receiving high-emetogenic chemotherapy for lung cancer. Methods: Using a Japanese national inpatient database, we identified patients who received olanzapine doses of 2.5 or 5 mg during high-emetogenic chemotherapy for lung cancer between January 2016 and March 2021. We conducted a 1:1 propensity score-matched analysis with adjustment for various factors, including those affecting olanzapine metabolism. The outcomes were additional antiemetic drug administration (within 2–5 days after chemotherapy initiation), length of hospital stay, and total hospitalization costs. Results: Olanzapine 2.5 and 5.0 mg were used in 2905 and 4287 patients, respectively. The propensity score-matched analysis showed that olanzapine 2.5 mg administration was significantly associated with a higher proportion of additional antiemetic drug administration (36% vs. 31%, p < 0.001) than olanzapine 5 mg. The median length of hospital stay was 8 days in both groups. Total hospitalization cost did not differ significantly between the two doses of olanzapine (5061 vs. 5160 USD, p = 0.07). The instrumental variable analysis demonstrated compatible results. Conclusion: Prophylactic use of olanzapine 2.5 mg during chemotherapy for lung cancer was associated with a higher rate of additional antiemetic drugs than olanzapine 5 mg.Keywords
Funding Information
- Ministry of Health, Labour and Welfare (23AA2003, 22AA2003, 22AA2003)
- The University of Tokyo
This publication has 41 references indexed in Scilit:
- Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based ChemotherapyJAMA Network Open, 2023
- Intergenerational comparison of 5-HT3RA in the prevention of chemotherapy-induced nausea and vomiting in gastric cancer patients receiving cisplatin-based chemotherapy: an observational study using a Japanese administrative claims databaseSupportive Care in Cancer, 2021
- A double‐blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamideCancer Medicine, 2020
- Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapySupportive Care in Cancer, 2020
- Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational studySupportive Care in Cancer, 2018
- 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk ChemotherapySupportive Care in Cancer, 2016
- Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokinesSupportive Care in Cancer, 2015
- Instrumental variable methods for causal inferenceStatistics in Medicine, 2014
- Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of lifeSupportive Care in Cancer, 2012
- A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanismEuropean Journal of Clinical Pharmacology, 1998